Jupiter Endovascular
Divya Bramharouthu is a highly skilled engineering professional with extensive experience in product development and research within the medical device industry. Currently serving as a Staff Product Development Engineer at Jupiter Endovascular since April 2025, Divya previously held positions as a Senior R&D Engineer at Imperative Care and Johnson & Johnson, where successful project leadership and innovative design in catheter systems and robotic devices were demonstrated. Divya's background includes a role as a Materials Engineer II at Medtronic, contributing technical leadership to key projects, and prior experience in research roles at Carnegie Mellon University, focusing on advanced biomedical engineering solutions. Divya holds a Master's degree in Bioengineering and Biomedical Engineering and a Bachelor of Science degree in Materials Science Engineering & Biomedical Engineering from Carnegie Mellon University.
This person is not in any teams
This person is not in any offices
Jupiter Endovascular
Imagine a world where you could bring the precision and control of surgery to catheter-based therapies. For decades, endovascular procedures have been constrained by the technological limitations of catheters that lose stability and control within the anatomy. We have created a new class of therapies to overcome these constraints by using Endoportal Control to mimic the precision and control of direct surgical access, while maintaining the minimally invasive profile of an endovascular intervention. Our vision is big, spanning the breadth of cardiovascular disease where we see compelling opportunities to reimagine therapies for millions of patients. Jupiter Endovascular is a medical technology startup located in the San Francisco Bay Area, led by a team of successful medical device entrepreneurs. We have big ambitions, with a culture built on innovation, teamwork, and speed. We have raised capital from a diversified investor base, including venture capital, private equity, corporate strategic investors, and clinician angel investors.